- Home
- RFI vs PRQR Comparison
RFI vs PRQR Comparison
Compare RFI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFI | PRQR |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.7M | 250.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | RFI | PRQR |
|---|---|---|
| Price | $11.09 | $2.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 69.8K | ★ 586.4K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.62 | $1.07 |
| 52 Week High | $12.52 | $3.10 |
Technical Indicators
Market Signals| Indicator | RFI | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 52.12 |
| Support Level | $10.90 | $1.92 |
| Resistance Level | $11.17 | $2.31 |
| Average True Range (ATR) | 0.11 | 0.15 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 71.54 | 67.95 |
Price Performance
Historical ComparisonAbout RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.